With investments soaring in projects exploring therapeutic applications of RNA interference (RNAi), the field has apparently begun a significant turnaround as investors have recently backed new deals and launched new startups on evidence of potency from human clinical trials. estab- lished pharmaceutical and biotech companies are reportedly investing in more RNAi programs, a development that has not escaped the attention of new investors, now that delivery systems have been improved and shown more clinical promise, unlike during the period following the 2008 economic downturn when the patience of large pharmaceuticals ran out and RNAi programs were terminated. See Nature Biotechnology, March 2014.